Subscribe to RSS
DOI: 10.1055/s-0031-1297174
Anticoagulation in Children Undergoing Cardiac Surgery
Publication History
Publication Date:
20 December 2011 (online)
ABSTRACT
Advances in medical and surgical care have resulted in improved survival of patients with congenital heart disease (CHD). Parallel to these progresses, an increasing number of immediate and long-term complications have been recognized. One important complication in CHD is the development of thrombosis. Children with a single functional cardiac ventricle usually require sequential steps of surgery: the initial Blalock-Taussig shunts (BTS) during the neonatal period, followed by the Glenn shunt, and finally, the Fontan shunt, the “definitive palliative” procedure. Surgery mostly involves cardiopulmonary bypass (CPB), which also affects the coagulation system and causes an inflammatory response. This article will review surgical procedures, such as BTS, Glenn shunt, and Fontan shunt, prosthetic mechanical valves, and CPB, and their risk of thrombotic complications. There is insufficient evidence and no consensus for optimal anticoagulant prophylaxis or treatment in children with CHD. Current recommendations are mostly based on adult data.
KEYWORDS
Pediatric cardiology - cardiac surgery - thrombosis - thromboprophylaxis - anticoagulation
REFERENCES
- 1 Boris J R, Harris M A. The use of anticoagulation in pediatric cardiac disease. Images Pediatr Cardiol. 2003; 16 1-35
- 2 Monagle P. Thrombosis in children with BT shunts, Glenns and Fontans. Prog Pediatr Cardiol. 2005; 21 17-21
- 3 Monagle P, Adams M, Mahoney M et al.. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000; 47 (6) 763-766
- 4 Blalock A. Physiopathology and surgical treatment of congenital cardiovascular defects. Harvey Lect. 1945–1946; 41 90-116
- 5 Glenn W W. Circulatory bypass of the right side of the heart. IV. Shunt between superior vena cava and distal right pulmonary artery; report of clinical application. N Engl J Med. 1958; 259 (3) 117-120
- 6 Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971; 26 (3) 240-248
- 7 Monagle P, Cochrane A, Roberts R et al.. A multicentre randomized trial comparing heparin/warfarin and aspirin as primary thromboprophylaxis for two years after fontan procedure in children. J Am Coll Cardiol. 2011; 58 645-651
- 8 Caldarone C A, Raghuveer G, Hills C B et al.. Long-term survival after mitral valve replacement in children aged <5 years: a multi-institutional study. Circulation. 2001; 104 (12, Suppl 1) I143-I147
- 9 Khitin L M, Sade R M, Bradley S M, Crawford Jr F A, Widener C E, Stroud M R. Prevention of thrombosis and embolism in children and adolescents with mechanical valve prostheses: warfarin versus antiplatelet agents. J Heart Valve Dis. 2006; 15 (3) 394-399 discussion 399
- 10 Tamisier D, Vouhé P R, Vernant F, Lecá F, Massot C, Neveux J Y. Modified Blalock-Taussig shunts: results in infants less than 3 months of age. Ann Thorac Surg. 1990; 49 (5) 797-801
- 11 Karpawich P P, Bush C P, Antillon J R, Amato J J, Marbey M L, Agarwal K C. Modified Blalock-Taussig shunt in infants and young children. Clinical and catheterization assessment. J Thorac Cardiovasc Surg. 1985; 89 (2) 275-279
- 12 Ahmad U, Fatimi S H, Naqvi I et al.. Modified Blalock-Taussig shunt: immediate and short-term follow-up results in neonates. Heart Lung Circ. 2008; 17 (1) 54-58
- 13 Norwood W I, Lang P, Hansen D D. Physiologic repair of aortic atresia-hypoplastic left heart syndrome. N Engl J Med. 1983; 308 (1) 23-26
- 14 Al Jubair K A, Al Fagih M R, Al Jarallah A S et al.. Results of 546 Blalock-Taussig shunts performed in 478 patients. Cardiol Young. 1998; 8 (4) 486-490
- 15 Tsai K T, Chang C H, Lin P J. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. J Cardiovasc Surg (Torino). 1996; 37 (2) 149-152
- 16 Wells W J, Yu R J, Batra A S, Monforte H, Sintek C, Starnes V A. Obstruction in modified Blalock shunts: a quantitative analysis with clinical correlation. Ann Thorac Surg. 2005; 79 (6) 2072-2076
- 17 Moulton A L, Brenner J I, Ringel R et al.. Classic versus modified Blalock-Taussig shunts in neonates and infants. Circulation. 1985; 72 (3 Pt 2) II35-II44
- 18 Gladman G, McCrindle B W, Williams W G, Freedom R M, Benson L N. The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot's tetralogy in the current era. J Thorac Cardiovasc Surg. 1997; 114 (1) 25-30
- 19 Karakurt C, Koçak G, Ozgen U. Recanalization of occluded modified Blalock-Taussig shunt with balloon angioplasty and intraarterial streptokinase. Anadolu Kardiyol Derg. 2008; 8 (1) 76-78
- 20 Monagle P, Chalmers E, Chan A American College of Chest Physicians et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (6, Suppl) 887S-968S
- 21 LeBlanc J, Albus R, Williams W G et al.. Serous fluid leakage: a complication following the modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg. 1984; 88 (2) 259-262
- 22 Mullen J C, Lemermeyer G, Bentley M J. Modified Blalock-Taussig shunts: to heparinize or not to heparinize?. Can J Cardiol. 1996; 12 (7) 645-647
- 23 Fenton K N, Siewers R D, Rebovich B, Pigula F A. Interim mortality in infants with systemic-to-pulmonary artery shunts. Ann Thorac Surg. 2003; 76 (1) 152-156 discussion 156-157
- 24 Motz R, Wessel A, Ruschewski W, Bürsch J. Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin. Cardiol Young. 1999; 9 (5) 474-477
- 25 Li J S, Yow E, Berezny K Y et al.. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?. Circulation. 2007; 116 (3) 293-297
- 26 Wessel D L, Berger F, Li J S, Fontecave S, Rakhit A, Newburger J W. for the CLARINET Investigators . A randomized trial of clopidogrel to reduce mortality and shunt-related morbidity in infants palliated with systemic to pulmonary artery shunt. Circulation. 2010; 122 A19459
- 27 Tanoue Y, Kado H, Boku N et al.. Three hundred and thirty-three experiences with the bidirectional Glenn procedure in a single institute. Interact Cardiovasc Thorac Surg. 2007; 6 (1) 97-101
- 28 Gewillig M. The Fontan circulation. Heart. 2005; 91 (6) 839-846
- 29 Pennington D G, Nouri S, Ho J et al.. Glenn shunt: long-term results and current role in congenital heart operations. Ann Thorac Surg. 1981; 31 (6) 532-539
- 30 Kopf G S, Laks H, Stansel H C, Hellenbrand W E, Kleinman C S, Talner N S. Thirty-year follow-up of superior vena cava-pulmonary artery (Glenn) shunts. J Thorac Cardiovasc Surg. 1990; 100 (5) 662-670 discussion 670-671
- 31 Koutlas T C, Harrison J K, Bashore T M, O'Laughlin M P, Tripp M E, Gaynor J W. Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Ann Thorac Surg. 1996; 62 (1) 258-261 discussion 261-262
- 32 Kuroczynski W. [Development of the Fontan procedure as therapeutic concept for children with complex congenital heart disease]. Herz. 2007; 32 (3) 241-247
- 33 Kaulitz R, Ziemer G, Luhmer I, Kallfelz H C. Modified Fontan operation in functionally univentricular hearts: preoperative risk factors and intermediate results. J Thorac Cardiovasc Surg. 1996; 112 (3) 658-664
- 34 Lemler M S, Scott W A, Leonard S R, Stromberg D, Ramaciotti C. Fenestration improves clinical outcome of the fontan procedure: a prospective, randomized study. Circulation. 2002; 105 (2) 207-212
- 35 Kaulitz R, Ziemer G, Rauch R et al.. Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastomosis). J Thorac Cardiovasc Surg. 2005; 129 (3) 569-575
- 36 Cromme-Dijkhuis A H, Henkens C M, Bijleveld C M, Hillege H L, Bom V J, van der Meer J. Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations. Lancet. 1990; 336 (8723) 1087-1090
- 37 Cromme-Dijkhuis A H, Hess J, Hählen K et al.. Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg. 1993; 106 (6) 1126-1132
- 38 Balling G, Vogt M, Kaemmerer H, Eicken A, Meisner H, Hess J. Intracardiac thrombus formation after the Fontan operation. J Thorac Cardiovasc Surg. 2000; 119 (4 Pt 1) 745-752
- 39 Coon P D, Rychik J, Novello R T, Ro P S, Gaynor J W, Spray T L. Thrombus formation after the Fontan operation. Ann Thorac Surg. 2001; 71 (6) 1990-1994
- 40 Seipelt R G, Franke A, Vazquez-Jimenez J F et al.. Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. Ann Thorac Surg. 2002; 74 (2) 556-562
- 41 Chun D S, Schamberger M S, Flaspohler T et al.. Incidence, outcome, and risk factors for stroke after the Fontan procedure. Am J Cardiol. 2004; 93 (1) 117-119
- 42 Stümper O, Sutherland G R, Geuskens R, Roelandt J R, Bos E, Hess J. Transesophageal echocardiography in evaluation and management after a Fontan procedure. J Am Coll Cardiol. 1991; 17 (5) 1152-1160
- 43 Fyfe D A, Kline C H, Sade R M, Gillette P C. Transesophageal echocardiography detects thrombus formation not identified by transthoracic echocardiography after the Fontan operation. J Am Coll Cardiol. 1991; 18 (7) 1733-1737
- 44 Heying R, van Oeveren W, Wilhelm S et al.. Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity. Crit Care. 2006; 10 (6) R165
- 45 Iyer G K, Van Arsdell G S, Dicke F P, McCrindle B W, Coles J G, Williams W G. Are bilateral superior vena cavae a risk factor for single ventricle palliation?. Ann Thorac Surg. 2000; 70 (3) 711-716
- 46 Bando K, Turrentine M W, Park H J, Sharp T G, Scavo V, Brown J W. Evolution of the Fontan procedure in a single center. Ann Thorac Surg. 2000; 69 (6) 1873-1879
- 47 Mair D D, Puga F J, Danielson G K. The Fontan procedure for tricuspid atresia: early and late results of a 25-year experience with 216 patients. J Am Coll Cardiol. 2001; 37 (3) 933-939
- 48 Petrossian E, Reddy V M, McElhinney D B et al.. Early results of the extracardiac conduit Fontan operation. J Thorac Cardiovasc Surg. 1999; 117 (4) 688-696
- 49 Giannico S, Santoro G, Marino B, Cicini M P, Marcelletti C. Bidirectional cavopulmonary anastomosis in congenital heart disease. Functional and clinical outcome. Herz. 1992; 17 (4) 234-241
- 50 Shirai L K, Rosenthal D N, Reitz B A, Robbins R C, Dubin A M. Arrhythmias and thromboembolic complications after the extracardiac Fontan operation. J Thorac Cardiovasc Surg. 1998; 115 (3) 499-505
- 51 Konstantinov I E, Puga F J, Alexi-Meskishvili V V. Thrombosis of intracardiac or extracardiac conduits after modified Fontan operation in patients with azygous continuation of the inferior vena cava. Ann Thorac Surg. 2001; 72 (5) 1641-1644
- 52 Abid F, Abid A, Fekih M, Zaouali R M, Ben Ismail M. Aortic valve replacement in children under 16 years of age with congenital or rheumatic valvular disease. A study of 64 cases. J Cardiovasc Surg (Torino). 1992; 33 (3) 265-271
- 53 Robbins R C, Bowman Jr F O, Malm J R. Cardiac valve replacement in children: a twenty-year series. Ann Thorac Surg. 1988; 45 (1) 56-61
- 54 Eaton M P, Iannoli E M. Coagulation considerations for infants and children undergoing cardiopulmonary bypass. Paediatr Anaesth. 2011; 21 (1) 31-42
- 55 Despotis G J, Avidan M S, Hogue Jr C W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001; 72 (5) S1821-S1831
- 56 Mojcik C F, Levy J H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001; 71 (2) 745-754
- 57 Guzzetta N A, Miller B E, Todd K, Szlam F, Moore R H, Tosone S R. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg. 2005; 100 (5) 1276-1282,table of contents
- 58 Koster A, Fischer T, Praus M et al.. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology. 2002; 97 (4) 837-841
- 59 Freed M D, Keane J F, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation. 1974; 50 (3) 565-569
- 60 Saxena A, Gupta R, Kumar R K, Kothari S S, Wasir H S. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Cathet Cardiovasc Diagn. 1997; 41 (4) 400-403
- 61 Bulbul Z R, Galal M O, Mahmoud E et al.. Arterial complications following cardiac catheterization in children less than 10 kg. Asian Cardiovasc Thorac Ann. 2002; 10 (2) 129-132
- 62 Grady R M, Eisenberg P R, Bridges N D. Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol. 1995; 25 (3) 725-729
- 63 Girod D A, Hurwitz R A, Caldwell R L. Heparinization for prevention of thrombosis following pediatric percutaneous arterial catheterization. Pediatr Cardiol. 1982; 3 (2) 175-180
- 64 Laurin S, Lundström N R. Venous thrombosis after cardiac catheterization in infants. Acta Radiol. 1987; 28 (3) 241-246
- 65 Miga D E, McKellar L F, Denslow S, Wiles H B, Case C L, Gillette P C. Incidence of femoral vein occlusion after catheter ablation in children: evaluation with magnetic resonance angiography. Pediatr Cardiol. 1997; 18 (3) 204-207
- 66 Hanslik A, Kitzmüller E, Thom K, Salzer-Muhar U, Michel-Behnke I, Male C. Comparison of high-dose vs low-dose heparinization protocols for prophylaxis of thrombotic complications during cardiac catheterization in children, HEARTCAT Study. J Thromb Hemost. 2011; in press
Katharina E. ThomM.D.
Department for Pediatric Cardiology, University Hospital for Children and Adolescent Medicine
Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
Email: katharina.thom@meduniwien.ac.at